Gossamer Bio, Inc. (NASDAQ:GOSS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been given an average rating of “Moderate Buy” by the six analysts that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $7.88.

A number of equities research analysts have issued reports on the stock. Piper Sandler reissued an “overweight” rating and set a $15.00 target price on shares of Gossamer Bio in a research note on Wednesday, March 27th. Oppenheimer initiated coverage on shares of Gossamer Bio in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $9.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a research note on Wednesday, May 8th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Gossamer Bio in a research note on Monday, May 20th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Gossamer Bio in a research note on Monday, June 17th.

Gossamer Bio Stock Performance

NASDAQ GOSS opened at $1.07 on Friday. Gossamer Bio has a twelve month low of $0.45 and a twelve month high of $1.60. The company has a debt-to-equity ratio of 7.37, a quick ratio of 7.13 and a current ratio of 7.13. The stock has a market cap of $242.06 million, a price-to-earnings ratio of -1.01 and a beta of 1.93. The firm’s 50 day moving average price is $0.81 and its two-hundred day moving average price is $0.94.

Gossamer Bio (NASDAQ:GOSS) last issued its earnings results on Tuesday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.19). Equities analysts anticipate that Gossamer Bio will post -0.41 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Faheem Hasnain bought 372,000 shares of the business’s stock in a transaction on Friday, June 21st. The stock was purchased at an average price of $0.67 per share, with a total value of $249,240.00. Following the transaction, the chief executive officer now directly owns 5,408,073 shares in the company, valued at $3,623,408.91. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 5.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Sivia Capital Partners LLC bought a new position in shares of Gossamer Bio during the 1st quarter worth about $29,000. SG Americas Securities LLC bought a new stake in Gossamer Bio in the first quarter valued at about $34,000. Sequoia Financial Advisors LLC increased its stake in Gossamer Bio by 27.2% in the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after acquiring an additional 20,000 shares during the period. Financial Advocates Investment Management increased its stake in Gossamer Bio by 35.0% in the fourth quarter. Financial Advocates Investment Management now owns 98,350 shares of the company’s stock valued at $90,000 after acquiring an additional 25,500 shares during the period. Finally, Citigroup Inc. increased its stake in Gossamer Bio by 9,916.9% in the third quarter. Citigroup Inc. now owns 196,732 shares of the company’s stock valued at $164,000 after acquiring an additional 194,768 shares during the period. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.